TW-37

Catalog No.S1121

TW-37 Chemical Structure

Molecular Weight(MW): 573.7

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 146 In stock
USD 160 In stock
USD 680 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

9 Customer Reviews

  • (a) H23 cells exposed for 0–24 h to TW-37 (10 uM) with and without ZVAD.fmk (50 uM) were monitored for apoptotic morphology using electron microscopy (scale bar, 5 mm). % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

    (b) Whole-cell lysates of H23 cells exposed for 0–24 h to TW-37 (10 uM) were probed with antibodies against PARP and caspase-9. The appearance of both the p89 processed form of PARP and the p35 form of caspase-9 were characteristic of the intrinsic pathway of apoptosis.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

  • (c) Whole-cell lysates of BAK-reconstituted and -deficient Jurkat cells exposed for 0–24 h to TW-37 (10 uM ) were probed as in B. % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

    (d) Electron micrographs of control and TW-37 (10 uM for 24 h); treated BAK-reconstituted and -deficient Jurkat cells reveal a dependence on BAK for TW-37- mediated apoptosis (scale bar, 5 um)

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

  • MCL-1 is a key anti-apoptotic BCL-2 family member that regulates ER membrane reorganisation. (a) Pan-BCL-2 family inhibitors induce ER membrane reorganisation more potently than BCL-2 and BCL-XL-specific inhibitors. Apogossypol (10 μM) and TW37 (20 μM) induced extensive membrane reorganisation, assessed by BAP31 staining in HeLa cells, within 4 h of exposure, whereas ABT-737 (20 μM) induced modest reorganisation after 8 h and the inactive enantiomer ABT-737E (20 μM) failed to induce reorganisation (scale bar, 20 μm).

    Cell Death Differ 2012 19, 1896-907. TW-37 purchased from Selleck.

    Cytotoxicity of TW-37 monotherapy. TTC549 cells and KP-MRTRY cells were seeded in 96-well plates, incubated for 24 h, treated with TW-37 (0-1,000 nM), and then analyzed. TW-37 IC50 values for the TTC549 and KP-MRT-RY cell lines were 554 and 588 nM, respectively.

    J Cell Physiol, 2016, 231(9):1932-40. TW-37 purchased from Selleck.

  • Sensitivity to ABT-199 and TW-37 in AML cell lines. Using ABT-199 and TW-37 to antagonise BCL-2 and MCL-1 respectively. The IC50s shown were obtained from alamar blue assays after treating 11 AML cell lines at a starting cell concentration of 2.5x105 /ml for 48 hours. Each cell line thawed is tested around the time of its final passage to authenticate its provenance using the Powerplex 16 kit to amplify short tandem repeats.

    PLoS One, 2018, 13(1): e0190682. TW-37 purchased from Selleck.

    MEF cells were treated for  24 hours with the Bcl-2 antagonists  TW-37at the indicated doses.Acute survival was monitored by propidium iodide uptake assays(red lines).Long term survival(red line) was measured by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

    Dr. Christine Hawkins of La Trobe University. TW-37 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100 nm TW-37.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. TW-37 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell Mmf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWn2V4d{UW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYhdk1? MnnLV2FPT0WU
human Ca9-22 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFIhdk1? M3HOUXNCVkeHUh?=
human CHL-1 cell NYH0R5JwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmK3TY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlkhdk1? NGfDcVJUSU6JRWK=
human A549 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\IXHBKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE4xQSCwTR?= NHTtVHlUSU6JRWK=
human RKO cell NE\5TJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF3LkG3JI5O MVzTRW5ITVJ?
human GCIY cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD64N{BvVQ>? MorjV2FPT0WU
human BHT-101 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NILmcpVKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOS56MzDuUS=> Mn\IV2FPT0WU
human Hs-578-T cell NYXZeWFNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mmj2TY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjV7IH7N MYXTRW5ITVJ?
human SK-UT-1 cell M1jE[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLC[W9KdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQC54ODDuUS=> NH3KWoZUSU6JRWK=
human NB7 cell MmHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLXUWFKdmirYnn0bY9vKG:oIHj1cYFvKE6ENzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK5MlI5KG6P NGTVVJJUSU6JRWK=
human YKG-1 cell MoDvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HVWGlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU44PiCwTR?= M2rYN3NCVkeHUh?=
human HuH-7 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jyN2lvcGmkaYTpc44hd2ZiaIXtZY4hUHWKLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNk45OiCwTR?= NX7SVJBrW0GQR1XS
human SAS cell NWPiZYdUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTSTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6xPEBvVQ>? MUTTRW5ITVJ?
human UACC-62 cell M3PGUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnCcXNKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC5|NTDuUS=> MnWwV2FPT0WU
human AGS cell NIDMPGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PSOWlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{euOVMhdk1? MnjPV2FPT0WU
human SK-MEL-30 cell Mnj0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWj2b2x2UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Nz65O{BvVQ>? M161c3NCVkeHUh?=
human A427 cell M{j1RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYTkT3JYUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFQvPjlibl2= NH\Xc|lUSU6JRWK=
human DU-145 cell Mkn0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYK5TWx{UW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5zMzDuUS=> NIrmd25USU6JRWK=
human HCT-116 cell M3fNcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{P1OGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUzNjZ4IH7N NUC2bXhJW0GQR1XS
human A673 cell M1vhdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1y2fWlvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzMlg2KG6P NF7IVZlUSU6JRWK=
human SF126 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUeuNFchdk1? M3HVWnNCVkeHUh?=
human SW872 cell MlrTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUiuPUBvVQ>? MlXyV2FPT0WU
human NCI-H1581 cell M{XRSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\lRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwNkSgcm0> M3vIV3NCVkeHUh?=
human SK-MEL-5 cell NEDPcVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXnkV|lkUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ7LkK1JI5O MkTTV2FPT0WU
human CP50-MEL-B cell NF\YPVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlnwTY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwNUmgcm0> NEezT4hUSU6JRWK=
human YH-13 cell NVu4[pZXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnP6TY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUewMlU6KG6P M3ToTHNCVkeHUh?=
human LXF-289 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4TyPGlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVczNjh3IH7N NWTCPGpWW0GQR1XS
human MC-IXC cell NHLV[4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe1MlM{KG6P NITpZoRUSU6JRWK=
human NB14 cell M3jvSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;KSJhKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Ok41PSCwTR?= MYnTRW5ITVJ?
human HEC-1 cell M3u4[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWrYd3c4UW6qaXLpeIlwdiCxZjDoeY1idiCKRVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgyNjN5IH7N MU\TRW5ITVJ?
human U-87-MG cell NIez[GZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJHUuQDdvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Nk4zPCCwTR?= Mm[zV2FPT0WU
human HOS cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXBd2tKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0MlcyKG6P MlrOV2FPT0WU
human HUTU-80 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4W2[WlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjBzIH7N MlPJV2FPT0WU
human A375 cell MkPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{j4RmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi4Mlg{KG6P NEXZ[IpUSU6JRWK=
human A204 cell NX;RbYwyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlHQTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUeuPFQhdk1? MnzmV2FPT0WU
human GB-1 cell NH:ycFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2TqUmlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm4MlY6KG6P MXXTRW5ITVJ?
human MDA-MB-231 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4rWbGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC4NFch|ryP NYDteWZlW0GQR1XS
human SW982 cell MnS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVA4KM7:TR?= M1G4TnNCVkeHUh?=
human SW756 cell NEfUNo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYXwXJVvUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{M{[g{txO MUjTRW5ITVJ?
human MG-63 cell NVfVS|E5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLBfmpyUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{NEig{txO MmDpV2FPT0WU
human Daoy cell M2LqVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3ju[mlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVQxPzNizszN MXrTRW5ITVJ?
human MDA-MB-453 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20OVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3MUi4JO69VQ>? MYfTRW5ITVJ?
human HT-144 cell MonVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVUzODFizszN MmnUV2FPT0WU
human LoVo cell NEDPRnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFk{KM7:TR?= MXfTRW5ITVJ?
human NY cell NFHPSIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zN{e2NkDPxE1? MorDV2FPT0WU
human SW1783 cell MoDmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE{ODFizszN M1q2S3NCVkeHUh?=
human A2780 cell M3XXZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVg1PiEQvF2= M{jNZXNCVkeHUh?=
human MDA-MB-361 cell M3zuTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{HJUWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK2OEDPxE1? M4f6b3NCVkeHUh?=
human RPMI-2650 cell NW\3dpN{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HUfWlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST2yOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{izNUDPxE1? MofoV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
+ Expand

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
+ Expand
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Formulation: TW-37 is resuspended in 1:1 Tween 80/ethanol (diluted 10-fold in 0.9% saline before use).
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID